ICON plc Overview
Pro stress-test →ICON plc is a world-leading clinical research organisation that delivers integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,100 employees in 97 locations in 55 countries as of December 31, 2025.
Strategic Profile
Pro stress-test →ICON's competitive edge remains its "FSP" model, which offers more flexibility to large pharmaceutical clients than its rivals. The shift toward "trial-at-home" models has accelerated since 2021, and ICON's early investment in mobile health through PRA has given it a first-mover advantage in decentralized trials. However, the company faces significant near-term headwinds from an ongoing accounting investigation.
Competitive Landscape
Pro stress-test →Syneos Health is a rival that went private in 2023 to restructure, now emerging as a leaner competitor in 2026. ICON competes in the Contract Research Organization (CRO) sector alongside major players like IQVIA. ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield.
Industry Context
ICON plc operates in Contract Research Organization (CRO) / Clinical Development Services.
Key facts
Founded: 1990 · Headquarters: Dublin, Ireland · Employees: 40,100 · Revenue: $8.28B (FY2024) · Market cap: $10.17B